Conclusions

  • Primovist®-enhanced MRI has an important role in the management of patients with liver lesions due to its unique imaging characteristics.
  • Primovist®-enhanced MRI provides more precise lesion localization and characterization than other imaging modalities, with specific benefits in screening, diagnosis, surgical planning, treatment, and monitoring during follow-up.
  • The high diagnostic confidence of Primovist®-enhanced MRI translates to a reduced requirement for additional diagnostic procedures and therefore cost savings.

    • 1
      Zech CJ, Ba-Ssalamah A, Berg T, et al. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol. 2020;30(1):370-382.
    • 2
      Guo J, Seo Y, Ren S, et al. Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY). 2016;41(10):1960-1972.
    • 3
      Lee JM, Kim MJ, Phongkitkarun S, et al. Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea. J Med Econ. 2016;19(8):759-768.
    • 4
      Choi SH, Byun JH, Kwon HJ, et al. The usefulness of gadoxetic acid-enhanced dynamic magnetic resonance imaging in hepatocellular carcinoma: toward improved staging. Ann Surg Oncol. 2015;22(3):819-825.
    • 5
      Rimola J, Forner A, Sapena V, et al. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol. 2020;30(1):186-194.
    • 6
      Oh JW, Oh SN, Choi JI, et al. Does the Gadoxetic Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with 18F-FDG PET/CT. Biomed Res Int. 2016;2016:8412071.
    • 7
      Schulz A, Viktil E, Godt JC, et al. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol. 2016;57(9):1040-1048.
    • 8
      Seo N, Park M-S, Han K, et al. Magnetic resonance imaging for colorectal cancer metastasis to the liver: comparative effectiveness research for the choice of contrast agents. Cancer Res Treat. 2018;50(1):60-70.
    • 9
      Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging Is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology. 2019;69(4):1599-1613.
    • 10
      Zech CJ, Grazioli L, Jonas E, et al. Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. Eur Radiol. 2009;19 Suppl 3:S753-763.
    • 11
      Zech CJ, Justo N, Lang A, et al. Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: results from the VALUE Trial. Eur Radiol. 2016;26(11):4121-4130.